Loading
ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms.
ARD103 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by ARCE Therapeutics, Inc., in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back.
1.ARD103 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ARD103" OR ABSTRACT:"ARD103") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARD103, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tags pipeline, registry-only.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags pipeline, registry-only.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags pipeline, registry-only.
Shares Acute myeloid leukaemia and the tags pipeline, registry-only.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags pipeline, registry-only.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.